Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01598025

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors.

This study is being done to test the safety and the treatment results of a specific kind of transplant. In this transplant, blood from two donors will be used. Each donor will share one half of your HLA type. Blood from both donors will be transplanted at the same time.

Status: 
Recruiting
Study Date: 
Tue, 05/01/2012 to Mon, 05/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Radiation: total-body irradiation (TBI) Drug: thiotepa Drug: fludarabine phosphate Drug: melphalan Biological: anti-thymocyte globulin Procedure: allogeneic hematopoietic stem cell transplantation Biological: peripheral blood stem cell transplantation Other: laboratory biomarker analysis